Reopening schools during the COVID-19 pandemic was linked with significantly lower rates of mental health diagnoses among children, including anxiety, depression, and attention-deficit/hyperactivity disorder (ADHD), and a drop in related health care spending, according to a new study from researchers at Harvard T.H. Chan School of Public Health and colleagues. The benefits were especially pronounced among girls.

A new decision framework developed by MIT researchers shows that, when patients with aggressive T-cell lymphoma relapse within 12 months of initial therapy, their chances for survival decline dramatically. This prognostic marker could help clinicians identify high-risk patients earlier.

New research on public attitudes toward AI indicates that most people are reluctant to let ChatGPT and other AI tools diagnose their health condition, but see promise in technologies that use AI to help diagnose cancer. These and other results of two nationally representative surveys will be presented at the annual meeting of the Society for Risk Analysis Dec. 7-10 in Washington, DC.

The negative health impacts from contamination by so called "forever chemicals" in drinking water costs the contiguous U.S. at least $8 billion a year in social costs, a University of Arizona-led study has found.

Measuring the lymphocytes (white blood cells that fight infection) in a patient’s blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to research from physicians at Fox Chase Cancer Center and Temple Health. 

A study funded in part by the National Institutes of Health (NIH) has revealed important insights into the genetics of deposits in the eye, known as reticular pseudodrusen (RPD), that are linked to greater risk of vision loss among people with age-related macular degeneration (AMD). The study underscores that AMD is not one disease and highlights the need for novel treatment approaches.  

As nuclear medicine theranostics expands rapidly across clinical practice worldwide, a new supplement to the Journal of Nuclear Medicine Technology (JNMT) explores how nuclear medicine technologists are embracing their growing role within the field. Titled, Building the Future of Theranostics: Advancing Practice, Education, and Innovation Worldwide, the supplement brings together voices from across the globe, offering perspectives that span clinical lessons, educational frameworks, operational strategies, advocacy, equity, and biology.